Merck announced the creation of the carlsbad (California, USA) a second enterprise for productive maintenance of the services we provide virus and gene therapy of BioReliance. It is assumed that the new commercial facility worth 100 million euros will be put into operation next year.
The Life Science company Merck in carlsbad produces a gene-therapy products for customers worldwide. Gene therapy is associated with the delivery of genetic material into cells of a patient for the correction of the mutated gene or redirect the immune cells to fight cancer. For the treatment of several diseases, including hemophilia and cancer, studies on the perspectives of using this technology.
According to the analysis of the international market, it is expected that the market for gene therapy, which was 1 billion dollars in 2018, will reach 2026 $ 10 billion.